Professor Christopher George

Publications

Journal Articles

  1. & The ryanodine receptor: advances in structure and organization. Current Opinion in Physiology 1C, 1-6.
  2. & Updating the guidelines for data transparency in the British Journal of Pharmacology - data sharing and the use of scatter plots instead of bar charts. British Journal of Pharmacology 174(17), 2801-2804.
  3. & Ryanodine receptors are part of the myospryn complex in cardiac muscle. Scientific Reports 7(1)
  4. & Massive Accumulation of Myofibroblasts in the Critical Isthmus Is Associated With Ventricular Tachycardia Inducibility in Post-Infarct Swine Heart. JACC: Clinical Electrophysiology 3(7), 703-714.
  5. & Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia. The Journal of Physiology 594(21), 6431-6432.
  6. & Pleiotropic mechanisms of action of perhexiline in heart failure. Expert Opinion on Therapeutic Patents 26(9), 1049-1059.
  7. & Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor. British Journal of Pharmacology 173(15), 2446-2459.
  8. & A Systemized Approach to Investigate Ca2+ Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes. Frontiers in Cell and Developmental Biology 3
  9. & The Mechanism of Flecainide Action in CPVT Does Not Involve a Direct Effect on RyR2. Circulation Research 116(8), 1324-1335.
  10. & Synergy Between Intercellular Communication and Intracellular Ca2+ Handling in Arrhythmogenesis. Annals of Biomedical Engineering 43(7), 1614-1625.
  11. & A New System for Profiling Drug-Induced Calcium Signal Perturbation in Human Embryonic Stem Cell–Derived Cardiomyocytes. Journal of Biomolecular Screening 20(3), 330-340.
  12. What really causes arrhythmias in heart failure?. British Society for Heart Failure Supplement, 18
  13. & A network-oriented perspective on cardiac calcium signaling. AJP: Cell Physiology 303(9), C897-C910.
  14. & Searching for new cardiovascular drugs: towards improved systems for drug screening?. Expert Opinion on Drug Discovery 6(11), 1155-1170.
  15. & Divergent effect of mammalian PLCζ in generating Ca2+oscillations in somatic cells compared with eggs. Biochemical Journal 438(3), 545-553.
  16. & How does CaMKII  phosphorylation of the cardiac ryanodine receptor contribute to inotropy?. Proceedings of the National Academy of Sciences 107(31), E123-E123.
  17. & Soluble TLR2 Reduces Inflammation without Compromising Bacterial Clearance by Disrupting TLR2 Triggering. The Journal of Immunology 183(1), 506-517.
  18. Evidence for serca and BK Ca activation in BNP protection of reperfused myocardium. Journal of Molecular and Cellular Cardiology 44
  19. Sarcoplasmic reticulum Ca2+ leak in heart failure: mere observation or functional relevance?. Cardiovascular Research 77(2), 302-314.
  20. & Refocussing therapeutic strategies for cardiac arrhythmias: defining viable molecular targets to restore cardiac ion flux. Expert Opinion on Therapeutic Patents 18(1), 1-19.
  21. Genetic polymorphisms in β1 and β2 adrenergic receptors: Variations without a theme?. Heart Rhythm 5(6), 822-825.
  22. & Ryanodine receptors and ventricular arrhythmias: Emerging trends in mutations, mechanisms and therapies. Journal of Molecular and Cellular Cardiology 42(1), 34-50.
  23. & Ryanodine receptor mutations in arrhythmias: advances in understanding the mechanisms of channel dysfunction. Biochemical Society Transactions 35(5), 946-951.
  24. & Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction. Current Pharmaceutical Design 13(31), 3195-3211.
  25. & Alternative Splicing of Ryanodine Receptors Modulates Cardiomyocyte Ca2+ Signaling and Susceptibility to Apoptosis. Circulation Research 100(6), 874-883.
  26. Ryanodine receptor mutations and ventricular arrhythmias: channel instability at the heart of Ca 2+ release dysfunction. Journal of Molecular and Cellular Cardiology 40
  27. & Role of ryanodine receptor mutations in cardiac pathology: more questions than answers?. Biochemical Society Transactions 34(5), 913-918.
  28. & Arrhythmogenic Mutation-Linked Defects in Ryanodine Receptor Autoregulation Reveal a Novel Mechanism of Ca2+ Release Channel Dysfunction. Circulation Research 98(1), 88-97.
  29. & Toward a Molecular Understanding of the Structure–Function of Ryanodine Receptor Ca2+ Release Channels: Perspectives From Recombinant Expression Systems. Cell Biochemistry and Biophysics 42(2), 197-222.
  30. & Is Fish Oil Good or Bad for Heart Disease? Two Trials with Apparently Conflicting Results. Journal of Membrane Biology 206(2), 155-163.
  31. & Differential Ca2+ sensitivity of RyR2 mutations reveals distinct mechanisms of channel dysfunction in sudden cardiac death. Biochemical and Biophysical Research Communications 331(1), 231-238.
  32. & Ryanodine receptor dysfunction in arrhythmia and sudden cardiac death. Future Cardiology 1(4), 531-541.
  33. & Ryanodine Receptor Regulation by Intramolecular Interaction between Cytoplasmic and Transmembrane Domains. Molecular Biology of the Cell 15(6), 2627-2638.
  34. & Functional heterogeneity of ryanodine receptor mutations associated with sudden cardiac death. Cardiovascular Research 64(1), 52-60.
  35. & Ryanodine Receptor Mutations Associated With Stress-Induced Ventricular Tachycardia Mediate Increased Calcium Release in Stimulated Cardiomyocytes. Circulation Research 93(6), 531-540.
  36. & In situ modulation of the human cardiac ryanodine receptor (hRyR2) by FKBP12.6. Biochemical Journal 370(2), 579-589.
  37. & Dysregulated Ryanodine Receptors Mediate Cellular Toxicity. Journal of Biological Chemistry 278(31), 28856-28864.
  38. CELL DEATH INDUCED BY OVEREXPRESSION OF THE HUMAN CARDIAC RYANODINE RECEPTOR (hRYR2) CAN BE PREVENTED BY CO-EXPRESSION WITH FK506-BINDING PROTEIN 12.6 (FKBP12. 6). Heart 85
  39. Targeted bioluminescent indicators in living cells. Methods in Enzymology 375, 479-498.
  40. & Analysis of Gap Junction Assembly Using Mutated Connexins Detected in Charcot-Marie-Tooth X-Linked Disease. Journal of Neurochemistry 74(2), 711-720.
  41. & Synthesis and assembly of connexins in vitro into homomeric and heteromeric functional gap junction hemichannels. Biochemical Journal 339(2), 247
  42. & Intracellular Trafficking Pathways in the Assembly of Connexins into Gap Junctions. Journal of Biological Chemistry 274(13), 8678-8685.
  43. & Rapid Determination of Gap Junction Formation Using HeLa Cells Microinjected with cDNAs Encoding Wild-Type and Chimeric Connexins. Biochemical and Biophysical Research Communications 247(3), 785-789.
  44. & Connexin-Aequorin Chimerae Report Cytoplasmic Calcium Environments along Trafficking Pathways Leading to Gap Junction Biogenesis in Living COS-7 Cells. Journal of Biological Chemistry 273(45), 29822-29829.
  45. & Assembly of Chimeric Connexin-Aequorin Proteins into Functional Gap Junction Channels. Journal of Biological Chemistry 273(3), 1719-1726.
  46. Reporting the Calcium Environment in Trafficking Pathways Leading to Gap Junction Biogenesis Using Connexin-Aequorin Chimerae. Gap Junctions: Proceedings of the 8th International Gap Junction Conference, Key Largo, Florida

Book Chapters

  1. & Decoding Ca2+ signals as a non-electrophysiological method for assessing drug toxicity in stem cell-derived cardiomyocytes. In Stem Cell-derived models in toxicology. (pp. 173-190).
  2. & Techniques and Methodologies to Study the Ryanodine Receptor at the Molecular, Subcellular and Cellular Level. In Calcium Signaling. (pp. 183-215).
  3. & Trafficking pathways leading to the formation of gap junctions. In Novartis Foundation Symposium.
  4. & Targeting connexin-aequorin chimera to the gap junction. In Gap junctions. (pp. 107-111).
  5. & Reporting the calcium environment in trafficking pathways leading to gap junction biogenesis using connexion-aequorin chimera. In

Conference Contributions

  1. (2016). Effect of flecainide derivatives on sarcoplasmic reticulum Ca2+ release confirms a lack of direct action on the cardiac ryanodine receptor. Presented at Biophysical Journal,The Physiological Society.
  2. (2016). Increased myofibroblast densities are specific to critical isthmus sites in post-infarct re-entrant ventricular tachycardia. Presented at Heart Rhythm Society,Heart Rhythm Society, San Francisco, May 2016..
  3. (2016). LAVA sites are histologically closely related to critical isthmus sites in post-infarct ventricular tachycardia. Presented at Heart Rhythm Society,
  4. (2015). Cellular characterisation of stromal cell and cardiomyocyte coupling at the critical isthmus in an in vivo swine model of post-infarction re-entrant ventricular tachycardia. Presented at Journal of Investigative Cardiac Electrophysiology,
  5. (2015). The mechanism of flecainide action in catecholaminergic polymorphic ventricular tachycardia does not involve a direct effect on the ryanodine receptor. Presented at Proceedings of The Physiological Society,The Physiological Society.
  6. (2015). Fundamental gating defects of sudden cardiac death-linked mutant cardiac ryanodine receptors determine Ca2+ release dynamics in cells. Presented at Proceedings of The Physiological Society,The Physiological Society.
  7. (2014). Predictive Drug Toxicity Profiling using a New Mode of Calcium Signal Analysis in Human Es-Derived Cardiomyocytes. Presented at Biophysical Journal,Elsevier.
  8. (2014). The Metabolic Modulator Perhexiline Induces Calcium-Cycling Dysfunction and Apoptosis in Cardiomyocyte Syncytia. Presented at Biophysical Journal,Elsevier.
  9. (2013). Manipulating RyR2 Ca2+ Signalling in Cardiomyocyte Networks using Morpholino Oligonucleotides. Presented at Biophysical Journal,Elsevier.
  10. (2013). An Assessment of Calcium Handling and Cardiovascular Drug-Profiling in Cytiva Embryonic Stem-Cell Derived Cardiomyocytes. Presented at Biophys J,Elsevier.
  11. (2013). Exploring the Link between Ca2+ Signalling and ATP Dynamics in Cardiomyocyte Dysfunction. Presented at Biophysical Journal,Elsevier.
  12. (2011). Ouabain is a Pharmacomimic of Mutant RyR2 Ca2+ Release Dysfunction but is not a Serum-Borne Trigger of CPVT. Presented at Biophysical Journal,Cell Press.
  13. (2011). Trans Complementation with the Common G1885E Polymorphism Attenuates Mutant RyR2 L433P Channel Dysfunction. Presented at Biophysical Journal,Cell Press.
  14. (2011). Targeted Inhibition of Connexin 43 Hemichannels Blunts Ca 2+-Induced Intercellular Dyssynchrony and ATP Efflux in Hl-1 Cardiomyocyte Syncitia. Presented at Biophysical Journal,Cell Press.
  15. (2010). Biophysical and Cellular Characterisation of Alternatively Spliced Isoforms of the Human Cardiac Ryanodine Receptor (RyR2). Presented at Biophysical Journal,Cell Press.
  16. (2010). Adaptive Retuning of Small Ca2+ Fluxes in Cardiomyocyte Syncytia Predicts the Response To Pro-Arrhythmic Stimuli. Presented at Biophys J,
  17. (2009). Investigating the Ca 2+-cycling basis of rhythmicity and synchronicity in coupled cardiomyocyte monolayers. Presented at Biophysical Journal,Cell Press.
  18. (2009). Decoding The Molecular Basis Of Anti-Apoptotic Cardiac Ca 2+ Signalling Via Human RyR2 Splice Variants. Presented at Biophysical Journal,Cell Press.
  19. (2009). An L433P Arrhythmia-linked Mutation In RyR2 Uncouples Agonist-evoked Ca 2+ Release From Homeostatic Ca 2+ Cycling. Presented at Biophysical Journal,Cell Press.
  20. (2009). Targeted Stabilisation Of The RyR2 I-Domain Restores Ca 2+ Handling And Intercellular Synchrony In Ouabain-disrupted Cardiac Cell Monolayers. Presented at Biophysical Journal,Cell Press.
  21. (2009). A G1885E RyR2 polymorphism modulates the caffeine sensitivity of an arrhythmia-linked mutation. Presented at Biophysical Journal,Cell Press.
  22. (2008). Mutation-linked instability underlies RyR2 channel hypersensitivity to serum-borne factors. Presented at Biophysical Journal,
  23. (2008). SALVO- a new analytical platform for decoding intracellular Ca2+ fluxes and evaluating anti-arrhythmic compounds. Presented at Biophysical Journal,
  24. (2008). Suppression of arrhythmogenic Ca2+ fluxes in cardiac cells using fragments of human RyR2. Presented at Biophysical Journal,
  25. (2007). Site-directed mutagenesis of Serine 2815 on the cardiac ryanodine receptor and resultant effects on channel function. Presented at Proceedings of The Physiological Society,The Physiological Society.
  26. (2007). Modulating intracellular Ca2+ signaling using recombinant fragments of the human cardiac ryanodine receptor. Presented at Biophysical Journal,
  27. (2007). Targeting the RyR2 I-domain as a novel strategy to correct mutationlinked Ca2+ release channel dysfunction.. Presented at BIOPHYSICAL JOURNAL,
  28. (2006). A novel cardiomyocyte FRET-based bioassay for investigating the molecular basis of RyR2 dysfunction in arrhythmogenesis. Presented at Biophysical Journal,
  29. (2006). Exercise-induced factors in human serum trigger abnormal Ca2+ release via cardiac ryanodine receptor (RyR2) mutations. Presented at Biophysical Journal,
  30. (2005). In situ characterisation of the Ca2+ sensitivity of cardiac RyR mutations reveals multiple mechanisms of channel dysfunction in sudden death. Presented at BIOPHYSICAL JOURNAL,
  31. (2005). Visualisation of intra-RyR2 interactions in HL-1 cardiomyocytes: novel FRET probes reveal a structural basis for Ca2+ channel dysfunction in arrhythmogenesis.. Presented at BIOPHYSICAL JOURNAL,
  32. (2004). Molecular mechanisms underlying RyR2 (Ca2+ release channel) dysfunction in stress-induced VT. Presented at BIOPHYSICAL JOURNAL,
  33. (2004). Characterisation of the human recombinant cardiac intracellular calcium release channel (ryanodine receptor).. Presented at BIOPHYSICAL JOURNAL,
  34. (2004). Altered intra-RyR interaction associated with stress-induced ventricular tachycardia.. Presented at BIOPHYSICAL JOURNAL,
  35. (2003). Expression of human RyR2 splice variants. Presented at BIOPHYSICAL JOURNAL,
  36. (2003). Transcriptional alterations mediated via dysregulated human cardiac ryanodine receptor (hRyR2).. Presented at BIOPHYSICAL JOURNAL,
  37. (2002). Cytoplasmic Ca2+ spiking via human RyR2 mediates cell death. Presented at BIOPHYSICAL JOURNAL,
  38. (2002). In situ regulation of the human cardiac ryanodine receptor (hRyR2) by intramolecular interaction. Presented at Biophysical Journal,
  39. (2001). In situ modulation of the human cardiac ryanodine receptor (hRyR2) by FKBP12. 6.. Presented at BIOPHYSICAL JOURNAL,

Other Research Outputs

  1. & (2006). Molecular Biology of Ryanodine Receptors. (Henry Stewart Life Sciences Collection). : Henry Stewart.